Global Allergy Diagnostics and Therapeutics Market Size Likely to Expand at a CAGR of 8.1% By 2033

As per the current market research conducted by the CMI Team, the global Allergy Diagnostics and Therapeutics Market size is expected to record a CAGR of 8.1% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 38,713.6 Million. By 2033, the valuation is anticipated to reach USD 78,036.1 Million.

Allergy Diagnostics and Therapeutics Market: Growth Factors and Dynamics

• Rising Prevalence of Allergic Conditions: The increasing prevalence of allergies globally, attributed to environmental factors, genetic predisposition, and lifestyle changes, continues to drive the demand for advanced allergy diagnostics and effective therapeutic options. This trend underscores the market’s growth trajectory as healthcare systems address the expanding burden of allergic diseases.

• Advancements in Diagnostic Technologies: Ongoing advancements in allergy diagnostic technologies, such as improved sensitivity and specificity in blood tests (serology) and enhanced precision in skin tests (skin prick tests and patch tests), are pivotal in enhancing diagnostic accuracy and efficiency. These innovations are crucial in meeting the growing demand for reliable and timely allergy diagnosis, thereby fueling market growth.

• Growing Demand for Personalized Medicine: There is a notable shift towards personalized medicine in allergy management, driven by the need for tailored treatment approaches based on individual allergen profiles and immune responses. This demand stimulates the development of targeted immunotherapy solutions and specialized diagnostic tools that cater to specific patient needs, contributing significantly to market expansion.

• Increasing Healthcare Expenditure: Globally, healthcare expenditure continues to rise, enabling greater accessibility to allergy diagnostics and therapeutics. Increased healthcare investment supports the adoption of advanced diagnostic technologies and the development of innovative treatment options, thereby fostering market growth and improving patient outcomes through effective allergy management.

• Expanding Allergen Exposure: Factors such as environmental pollution, changes in dietary habits, and globalization contribute to the expansion of allergen exposure among populations worldwide. This heightened allergen exposure necessitates robust allergy diagnostics and therapeutics that can effectively identify allergens and provide targeted treatments, driving market demand and innovation in allergy management solutions.

• Regulatory Support and Guidelines: Supportive regulatory frameworks and guidelines play a crucial role in shaping the allergy diagnostics and therapeutics market. Clear regulatory pathways ensure the safety, efficacy, and quality of diagnostic tests and therapeutic interventions, fostering confidence among healthcare providers and patients. Regulatory support promotes standardization in allergy management practices, encouraging investment in research and development and facilitating market growth.

Allergy Diagnostics and Therapeutics Market: Partnership and Acquisitions

• In 2023, Astria Therapeutics, Inc. has announced a license agreement with Inchon’s Sciences, focusing on the OX40 portfolio, specifically STAR-0310. This collaboration aims to advance STAR-0310 for potential treatments targeting atopic dermatitis (AD) and other allergic and immunological conditions.

• In 2022, Allergy Partners collaborated with Aimmune Therapeutics to provide PALFORZIA, an FDA-approved treatment for peanut allergy, directly to patients aged 4-17. This initiative, facilitated through Allergy Partners Therapeutics (APT), expands access to PALFORZIA across Allergy Partners’ national network.

• In 2022, Oncologica, a healthcare testing laboratory based in Cambridge, introduced a novel Allergy Focus Test. This test aims to help individuals identify specific global allergens that trigger their body’s allergic reactions, offering targeted insights to manage allergies more effectively.

Report Scope

Allergy Diagnostics and Therapeutics Market: COVID-19 Analysis

The COVID-19 pandemic has significantly impacted the Allergy Diagnostics and Therapeutics Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:

• Disruption in Healthcare Services: During the COVID-19 pandemic, there was a significant disruption in non-urgent healthcare services, including allergy diagnostics and treatments. Many elective procedures, including allergy testing and immunotherapy sessions, were postponed or canceled, affecting market demand.

• Shift in Patient Priorities and Access: Patient priorities shifted towards COVID-19 testing and management, leading to reduced visits for routine allergy diagnostics and treatments. Access to healthcare facilities was also limited, impacting the uptake of allergy services and products.

• Resumption of Elective Procedures: As COVID-19 cases decline and healthcare systems stabilize, there is a gradual resumption of elective procedures, including allergy diagnostics and immunotherapy sessions. This recovery phase helps restore patient volumes and revenue streams for providers.

• Telehealth and Remote Monitoring: The adoption of telehealth and remote monitoring solutions surged during the pandemic, facilitating continuity of care for allergy patients. Virtual consultations and remote monitoring of symptoms and treatment progress became common, enhancing accessibility to allergy services.

• Focus on Patient Safety Protocols: Enhanced safety protocols, including infection control measures and social distancing guidelines, were implemented in healthcare settings. These measures instilled confidence among patients to resume allergy diagnostics and treatments, supporting market recovery.

• Expansion of Allergy Testing Capacities: Healthcare facilities expanded their capacity for allergy testing to accommodate pent-up demand and backlogs caused by the pandemic. Increased availability of diagnostic tests facilitated timely identification of allergies and initiation of appropriate treatments.

• Government Support and Policy Changes: Governments and healthcare authorities implemented supportive policies and funding initiatives to mitigate the impact of COVID-19 on healthcare services, including allergy diagnostics and therapeutics. Financial aid and regulatory flexibility helped healthcare providers adapt and recover from pandemic-related disruptions.

In conclusion, the COVID-19 pandemic has had a mixed impact on the Allergy Diagnostics and Therapeutics Market, with some challenges and opportunities arising from the pandemic.

List of the prominent players in the Allergy Diagnostics and Therapeutics Market:

• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG
• Danaher Corporation
• Hitachi Chemical Diagnostics Inc.
• Omega Diagnostics Group PLC
• bioMérieux SA
• Hycor Biomedical Inc.
• Lincoln Diagnostics Inc.
• Stallergenes Greer PLC
• HAL Allergy Group
• Biomay AG
• Indoor Biotechnologies Inc.
• R-Biopharm AG
• ALK-Abelló A/S
• Leti Pharma GmbH
• Others

The Allergy Diagnostics and Therapeutics Market is segmented as follows:

By Product Type

• Instruments
• Consumables
• Therapeutics
• Others

By Test Type

• Skin Tests
• Blood Tests
• Provocation Tests
• Elimination Diet Tests
• Others

By Allergen Type

• Inhaled Allergens
• Food Allergens
• Drug Allergens
• Others

By End User

• Hospitals & Clinics
• Diagnostic Laboratories
• Research Institutes
• Others

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America